Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma
Public ClinicalTrials.gov record NCT02285062. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase 3 Randomized, Double-Blind, Placebo Controlled, Multicenter Study to Compare the Efficacy and Safety of Lenalidomide (CC-5013) Plus R-CHOP Chemotherapy (R2-CHOP) Versus Placebo Plus R-CHOP Chemotherapy in Subjects With Previously Untreated Activated B-cell Type Diffuse Large B-cell Lymphoma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
To evaluate the efficacy and safety of lenalidomide, rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R2-CHOP) chemotherapy versus placebo, rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (placebo-R-CHOP) chemotherapy in patients who have previously untreated ABC type DLBCL.
Study identification
- NCT ID
- NCT02285062
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 570 participants
Conditions and interventions
Conditions
Interventions
- lenalidomide Drug
- Placebo Drug
- Rituximab Drug
- Cyclophosphamide Drug
- Doxorubicin Drug
- prednisone Drug
- vincristine Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 80 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 17, 2015 (Actual)
- Primary completion
- Mar 15, 2019 (Actual)
- Completion
- Jul 28, 2022 (Actual)
- Last update posted
- Jun 22, 2023
2015 – 2022
United States locations
- U.S. sites
- 22
- U.S. states
- 14
- U.S. cities
- 19
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Local Institution - 177 | Fayetteville | Arkansas | 72703 | — |
| Local Institution - 136 | Orange | California | 92868 | — |
| Local Institution - 127 | Sacramento | California | 95817 | — |
| Local Institution - 169 | New Haven | Connecticut | 06510 | — |
| Local Institution - 128 | Hollywood | Florida | 33021 | — |
| McFarland Clinic | Ames | Iowa | 50010-3014 | — |
| Siouxland Hematology-Oncology Associates, LLP | Sioux City | Iowa | 51101-1733 | — |
| Local Institution - 143 | Fairway | Kansas | 66205 | — |
| Local Institution - 158 | Shreveport | Louisiana | 71103 | — |
| Center For Cancer And Blood Disorders | Bethesda | Maryland | 20817 | — |
| Local Institution - 101 | Minneapolis | Minnesota | 55416 | — |
| Local Institution - 138 | Minneapolis | Minnesota | 55455 | — |
| Local Institution - 112 | Rochester | Minnesota | 55905 | — |
| Local Institution - 103 | Durham | North Carolina | 27710 | — |
| Local Institution - 161 | Philadelphia | Pennsylvania | 19111 | — |
| Local Institution - 951 | Dallas | Texas | 75235 | — |
| Local Institution - 151 | Dallas | Texas | 75390-9068 | — |
| Local Institution - 146 | Salt Lake City | Utah | 84106 | — |
| Local Institution - 905 | Edmonds | Washington | 98026 | — |
| Local Institution - 903 | Issaquah | Washington | 98029 | — |
| Local Institution - 162 | Seattle | Washington | 98104 | — |
| Local Institution - 904 | Seattle | Washington | 98107 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 136 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02285062, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 22, 2023 · Synced Oct 24, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02285062 live on ClinicalTrials.gov.